Endothelin-1 and Human Platelets

Author(s): I. Anita Jagroop, Stella S. Daskalopoulou, Dimitri P. Mikhailidis

Journal Name: Current Vascular Pharmacology

Volume 3 , Issue 4 , 2005

Become EABM
Become Reviewer
Call for Editor


There is conflicting evidence regarding the effect of endothelin-1 (ET-1) on platelets. Some studies show that ET-1 activates platelets, others show platelet inhibition with ET-1 and some studies did not detect an effect of ET-1. These conflicting results may be due to complex interactions between platelet ETA and ETB receptors. ET-1 antagonism may emerge as an important therapeutic strategy in the management of several vascular disorders. However, to date the only prescribed ET-1 antagonist is bosentan for pulmonary arterial hypertension. Bosentan is a dual ET- 1 antagonist (i.e. it acts on both ETA and ETB receptors). Whether this action involves an effect on platelets remains to be established. In this review some of the studies describing the effect of ET-1 on human platelets are discussed. Vascular diseases where ET-1 is implicated are also considered.

Keywords: endothelin, platelet, bosentan, pulmonary hypertension, vascular disease

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Published on: 01 March, 2012
Page: [393 - 399]
Pages: 7
DOI: 10.2174/157016105774329453
Price: $65

Article Metrics

PDF: 11